ProSomnus™ Sleep Technologies is dedicated to helping dentists treat the growing number of patients with Obstructive Sleep Apnea.
San Francisco, CA, June 9, 2016 – MicroDental Laboratories today announced the launch of ProSomnus Sleep Technologies, featuring the award-winning MicrO2™ Sleep Apnea Device. This strategic move enables ProSomnus to better align and focus resources with the needs of dentists who are treating the rapidly growing number of adults with Obstructive Sleep Apnea (OSA), a Sleep Breathing Disorder that is associated with a 4 to 5-fold increase in mortality and affects over 20 Million adults in the United States.
“After carefully considering the dental sleep medicine opportunity and MicroDental’s capabilities, the Executive Team agreed that a focused operation has the most potential to create value for dentists, their patients, employees and shareholders,” stated William Johnson, CEO of MicroDental Laboratories.
At launch, Len Liptak, who is currently President of MicroDental Laboratories, will serve in a dual capacity as CEO of ProSomnus Sleep Technologies. Len is an experienced dental industry leader, with expertise operating and developing businesses driven by product innovation.
“ProSomnus invents and manufactures custom intraoral devices that enable dentists to treat Obstructive Sleep Apnea with greater effectiveness, efficiency and convenience,” stated Len Liptak, CEO of ProSomnus Sleep Technologies. “This strategy enables ProSomnus to accelerate key product development, process enhancement and patient education programs.”
Dr. Dave Kuhns, PhD., and Sung Kim are also slated to play a leadership role with ProSomnus Sleep Technologies. Dave and Sung each have invented and commercialized numerous orthodontic, dental restorative and prosthetic, and dental sleep medicine products. Dave Kuhns joins ProSomnus as Vice President of Technology. Sung Kim joins ProSomnus as Vice President of Engineering.
“ProSomnus is the only company that precision manufactures intraoral devices, such as the MicrO2 Device, for the treatment of Obstructive Sleep Apnea,” noted Sung Kim, VP of Engineering. “Our proprietary manufacturing platform allows ProSomnus to meet clinical requirements in terms of function, features, and also consistency, reliability and service.”
“ProSomnus is focused on commercializing device designs that are clinically relevant, creating treatment experiences that exceed the needs of the practicing sleep dentist, and supporting scientific research that further establishes dental sleep medicine as a viable therapy for OSA,” added Dave Kuhns, VP of Technology.
AADSM 25th Anniversary Meeting
ProSomnus Sleep Technologies is scheduled to debut at the 25th Anniversary American Academy of Dental Sleep Medicine (AADSM) Annual Meeting. The meeting takes place from June 9-11, 2016, in Denver, CO. The company is hosting a kickoff event on Thursday evening at 6pm, featuring the presentation of a randomized controlled trial, a retrospective cohort study and a case series report featuring the MicrO2 Sleep Device.
About Obstructive Sleep Apnea and Dental Sleep Medicine
Obstructive Sleep Apnea is a Sleep Breathing Disorder characterized by a limitation, or complete cessation, of breathing during sleep. Obstructive Sleep Apnea is correlated with a 4 to 5 fold increase in mortality, and associated with major medical conditions including heart failure, cancer, stroke and diabetes. Over 100 Million adults worldwide and 20 Million adults in the United States suffer from OSA. Despite the significant health risks, over 80% of adults suffering from OSA remain undiagnosed. The economic cost of untreated OSA in the United States is estimated to be between $65 and $165 Billion.
Signs and symptoms of Obstructive Sleep Apnea may include snoring, lack of energy, excessive daytime sleepiness, morning headaches and depression.
Intraoral devices, fitted by dentists, are emerging as an effective therapy for Obstructive Sleep Apnea. Intraoral devices work by precisely positioning the jaw in a position that opens up the airway. Though CPAP remains the gold standard therapy and physicians must diagnose patients, dentists are playing an increasing role in screening at-risk patients, treating patients who are prescribed oral appliances, or treating the greater than 50% of patients who abandon CPAP therapy.
About ProSomnus Sleep Technologies
ProSomnus Sleep Technologies designs, manufactures and markets innovative intraoral sleep devices that dentists use to treat patients diagnosed with Obstructive Sleep Apnea. The company’s flagship product is the MicrO2™ Sleep Device. The MicrO2 Sleep Device is a FDA Cleared Class II Medical Device that is smaller, stronger, more biocompatible, and more precise than predicate intraoral sleep apnea devices, allowing dentists to get patients into therapy faster, and with greater comfort and convenience. The MicrO2 has been used to treat thousands of patients, with clinical performance that has been validated in randomize controlled trials, retrospective cohort studies, and numerous clinical case reports.
About MicroDental Laboratories
MicroDental Laboratories is one of the leading dental laboratories, servicing dental practices in the United States, Canada, and cosmetic dentists worldwide. Offering world-class quality and personalized service, MicroDental aims to help dentists create an exceptional and convenient treatment experience for each and every patient. MicroDental is DAMAS accredited, a Certified Dental Laboratory, and features one of the highest ratios of Certified Dental Technicians to cases in the industry. MicroDental makes all restorations in the USA, uses FDA accepted materials, and utilizes the Identalloy/Identceram material verification systems.